AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
Latest Information Update: 17 Oct 2023
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Registrational
- Acronyms GLITTER 2
- Sponsors Gan&Lee Pharmaceuticals
- 13 Oct 2023 According to a Gan&Lee Pharmaceuticals media release, data from this study were presented at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting.
- 13 Oct 2023 Results presented in a Gan&Lee Pharmaceuticals media release.
- 06 Oct 2023 Primary endpoint has been met. (Treatment-induced Anti-Insulin Antibody (TI-AIA) is the Primary Endpoint)